RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) | Rumor.io

Rhythm Pharmaceuticals

RYTM

Attention (50-day avg)0%

Attention rank (50-day avg)#2,152

Bullish sentiment (50-day avg)95%

Price to earnings ratio-31.7

Market capitalization6.8B

Earnings per share-3.12

Dividend yield (TTM)—

Revenue (annual)189.8M

Net income (annual)-196.5M

Social

What share of all stock conversation is about RYTM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 20

$RYTM shares are trading higher after the company received FDA approval for an expanded indication for IMCIVREE to treat patients with acquired hypothalamic obesity.
The approval opens a new market opportunity with strong clinical results and immediate US availability, and the stock price has risen by +7.3% as a result.
Rhythm Pharmaceuticals' IMCIVREE is the first and only FDA-approved therapy for acquired hypothalamic obesity, which affects patients with brain damage related obesity.

Generated by AI

Sentiment

Of the messages about RYTM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +5.59	88.5% -5.18
Bearish	—	—	0% -5.59	11.5% +5.18

Bullish· Mar 20

Rhythm Pharmaceuticals has secured a critical FDA label expansion for its obesity drug setmelanotide, opening the door to treating acquired hypothalamic obesity.
The FDA approval of IMCIVREE, Rhythm's new drug, is expected to have an immediate sales impact of roughly 25k-28k patients, with potential for further growth.
Citigroup and Leerink Partners have raised their target prices for Rhythm Pharmaceuticals to $142, indicating strong bullish sentiment among analysts.

Bearish· Jul 22

The asset's short interest has been covered, with some investors thinking it may have found a bottom at $13.6.
The company may be planning an offering, which could lead to dilution of shares and a drop in price.
The asset's high price may be unsustainable, with some investors predicting a significant drop in price due to the small target market for its drug.

Generated by AI

Topics

Of the messages about RYTM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	81.89%
Analysts	—	0%	0%	6.9%
Macro	—	0%	0%	1.19%
Earnings	—	0%	0%	1.64%
Controversies	—	0%	0%	0%
Technical Analysis	—	0%	0%	8.38%

Earnings· Nov 8

Rhythm Pharmaceuticals Inc $RYTM is expected to post earnings of -$0.41 per share.
-$0.41 earnings per share are expected for Rhythm Pharmaceuticals Inc $RYTM this quarter.
Rhythm Pharmaceuticals Inc $RYTM's earnings are expected to be -$0.41 per share.

Announcements· Mar 20

The FDA has approved an expanded indication for Rhythm Pharmaceuticals' (RYTM) IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, a rare condition.
This approval marks the first and only FDA-approved therapy for acquired hypothalamic obesity and expands the eligible patient population to include adults and pediatric patients aged 4+.
The expanded indication is expected to present a significant new market opportunity for RYTM, with immediate US availability and strong clinical results supporting the therapy's effectiveness.

Generated by AI

Community

Of the messages about RYTM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	71.43%	81.3%
Newcomers	—	100%	28.57%	18.7%

Regulars· Dec 11

The preliminary data from Rhythm Pharmaceuticals' Phase 2 trial of setmelanotide showed a positive efficacy signal in Prader-Willi Syndrome, with reductions in BMI and hyperphagia after three an.
The results, which demonstrated a positive efficacy signal, were announced by Rhythm Pharmaceuticals, and the company's stock price increased by 14.29% as a result.
The data from the exploratory Phase 2 trial showed that setmelanotide demonstrated a positive efficacy signal in Prader-Willi Syndrome, with a reduction in BMI and hyperphagia after treatment.

Newcomers· Mar 20

The FDA has approved Rhythm Pharmaceuticals' IMCIVREE for an expanded indication to treat acquired hypothalamic obesity, making it the first and only FDA-approved therapy for this condition.
The expanded indication will increase the eligible patient population, which could lead to a bigger revenue runway for the company, as IMCIVREE is its only commercial product.
The approval is expected to open up a significant new market for Rhythm Pharmaceuticals' setmelanotide, with a potential new patient population of 25,000 to 28,000, and may lead to increased options flow as traders position for the news.

Generated by AI

News

Rhythm Pharmaceuticals president & CEO Meeker sells $5.13m stock

15d agoInvesting.com

Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical

19d agoBarchart.com

Also Discussed

Investors talking about RYTM also mention

#	Name	Attention
1	TERN - Terns Pharmaceuticals, Inc.	——
2	ETNB - 89bio, Inc.	——
3	Mirum Pharmaceuticals, Inc.MIRM	0%0
4	IDEAYA Biosciences Inc.IDYA	0%-0.01
5	APLS - Apellis Pharmaceuticals, Inc.	——
6	Vaxcyte Inc.PCVX	0%0
7	Crinetics Pharmaceuticals IncCRNX	0%new
8	SWTX - SpringWorks Therapeutics, Inc.	——
9	Ascendis Pharma A/SASND	0%new
10	Travere Therapeutics Inc.TVTX	0%0

Rhythm Pharmaceuticals, Inc.

Healthcare
Biotechnology

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases. The company’s lead product, IMCIVREE (setmelanotide), is a precision medicine used to treat severe obesity and hyperphagia associated with specific melanocortin-4 receptor pathway disorders and acquired hypothalamic obesity. Rhythm Pharmaceuticals serves patients with serious rare conditions that are often underserved by conventional obesity treatments, and its work centers on targeted treatments designed for defined genetic and clinical populations. Based in Boston, Massachusetts, and founded in 2008, the company operates within specialty medicine, where it addresses unmet needs in rare metabolic and endocrine diseases through approved therapies and ongoing clinical development.

Website

Location

222 Berkeley Street

Boston, MA, 02116

United States

Social

What share of all stock conversation is about RYTM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 20

$RYTM shares are trading higher after the company received FDA approval for an expanded indication for IMCIVREE to treat patients with acquired hypothalamic obesity.
The approval opens a new market opportunity with strong clinical results and immediate US availability, and the stock price has risen by +7.3% as a result.
Rhythm Pharmaceuticals' IMCIVREE is the first and only FDA-approved therapy for acquired hypothalamic obesity, which affects patients with brain damage related obesity.

Generated by AI

Sentiment

Of the messages about RYTM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +5.59	88.5% -5.18
Bearish	—	—	0% -5.59	11.5% +5.18

Bullish· Mar 20

Rhythm Pharmaceuticals has secured a critical FDA label expansion for its obesity drug setmelanotide, opening the door to treating acquired hypothalamic obesity.
The FDA approval of IMCIVREE, Rhythm's new drug, is expected to have an immediate sales impact of roughly 25k-28k patients, with potential for further growth.
Citigroup and Leerink Partners have raised their target prices for Rhythm Pharmaceuticals to $142, indicating strong bullish sentiment among analysts.

Bearish· Jul 22

The asset's short interest has been covered, with some investors thinking it may have found a bottom at $13.6.
The company may be planning an offering, which could lead to dilution of shares and a drop in price.
The asset's high price may be unsustainable, with some investors predicting a significant drop in price due to the small target market for its drug.

Generated by AI

Topics

Of the messages about RYTM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	81.89%
Analysts	—	0%	0%	6.9%
Macro	—	0%	0%	1.19%
Earnings	—	0%	0%	1.64%
Controversies	—	0%	0%	0%
Technical Analysis	—	0%	0%	8.38%

Earnings· Nov 8

Rhythm Pharmaceuticals Inc $RYTM is expected to post earnings of -$0.41 per share.
-$0.41 earnings per share are expected for Rhythm Pharmaceuticals Inc $RYTM this quarter.
Rhythm Pharmaceuticals Inc $RYTM's earnings are expected to be -$0.41 per share.

Announcements· Mar 20

The FDA has approved an expanded indication for Rhythm Pharmaceuticals' (RYTM) IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, a rare condition.
This approval marks the first and only FDA-approved therapy for acquired hypothalamic obesity and expands the eligible patient population to include adults and pediatric patients aged 4+.
The expanded indication is expected to present a significant new market opportunity for RYTM, with immediate US availability and strong clinical results supporting the therapy's effectiveness.

Generated by AI

Community

Of the messages about RYTM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	71.43%	81.3%
Newcomers	—	100%	28.57%	18.7%

Regulars· Dec 11

The preliminary data from Rhythm Pharmaceuticals' Phase 2 trial of setmelanotide showed a positive efficacy signal in Prader-Willi Syndrome, with reductions in BMI and hyperphagia after three an.
The results, which demonstrated a positive efficacy signal, were announced by Rhythm Pharmaceuticals, and the company's stock price increased by 14.29% as a result.
The data from the exploratory Phase 2 trial showed that setmelanotide demonstrated a positive efficacy signal in Prader-Willi Syndrome, with a reduction in BMI and hyperphagia after treatment.

Newcomers· Mar 20

The FDA has approved Rhythm Pharmaceuticals' IMCIVREE for an expanded indication to treat acquired hypothalamic obesity, making it the first and only FDA-approved therapy for this condition.
The expanded indication will increase the eligible patient population, which could lead to a bigger revenue runway for the company, as IMCIVREE is its only commercial product.
The approval is expected to open up a significant new market for Rhythm Pharmaceuticals' setmelanotide, with a potential new patient population of 25,000 to 28,000, and may lead to increased options flow as traders position for the news.

Generated by AI

Rhythm Pharmaceuticals

Social

Mar 20

Bullish· Mar 20

Bearish· Jul 22

Earnings· Nov 8

Announcements· Mar 20

Regulars· Dec 11

Newcomers· Mar 20

Rhythm Pharmaceuticals president & CEO Meeker sells $5.13m stock

Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical

Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction

Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock

Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock

Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock

Also Discussed

Rhythm Pharmaceuticals, Inc.

Company Information

Location

Rhythm Pharmaceuticals president & CEO Meeker sells $5.13m stock

Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical

Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction

Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock

Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock

Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock

Also Discussed

Social

Mar 20

Bullish· Mar 20

Bearish· Jul 22

Earnings· Nov 8

Announcements· Mar 20

Regulars· Dec 11

Newcomers· Mar 20